Disbarment Sample Clauses

Disbarment. Contractor is prohibited from participation in any Program for any of the Utilities.
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Disbarment. The Contractor certifies that the said Contractor is not presently debarred, suspended or otherwise prohibited from doing public construction work in the Commonwealth of Massachusetts. Contractor shall immediately notify Town if at any time during the term of this Agreement it becomes debarred, suspended or otherwise prohibited from doing public construction work in the Commonwealth of Massachusetts.
Sample 1Sample 2
Disbarment. Vendor warrants that it is not disbarred or suspended, proposed for disbarment or declared ineligible for award of contracts by any federal agency.
Sample 1Sample 2
Disbarment. Neither Grantee nor any entity participating in the administration of the program is or will be disbarred from doing business with the Federal Government. GRANTEE UNITED STATES DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT By: ____________________________ By: _________________________ State or Commonwealth of Name: _________________________ ____________________________ Title: __________________________ ____________________________ Authorized Official Name: ______________________ Title: _______________________ ATTACHMENTS Exhibit 1 Definitions Exhibit 2 Fiscal Year _______ Section 811 Project Rental Assistance NOFA Exhibit 3 Inter-Agency Partnership Agreement Exhibit 4 Grantee Program Description (Identifying Grant Amount, Total Assisted Units & Identification of Other Parties Assisting Grantee in Executing the Cooperative Agreement) Exhibit 5 Program Guidelines Exhibit 6 Budget / Schedule Exhibit 7 Agreement to Enter into Rental Assistance Contract, Form HUD-92240-PRA Exhibit8 Rental Assistance Contract Part I, Form HUD-92235-PRA Exhibit9 Rental Assistance Contract Part II, Form HUD-92237-PRA Exhibit 11 Use Agreement, Form HUD-92238-PRA Exhibit10 Section 811 Project Rental Assistance Model Lease, Form HUD-92236-PRA Exhibit 12 Grantee Addendums Exhibit 1 of the Cooperative Agreement DEFINITIONS [NOTE: The definitions below are applicable to the Section 811 Project Rental Assistance program (811 PRA) and related contracts, such as the Cooperative Agreement and Exhibits, including the Rental Assistance Contract and Program Guidelines. All the terms below do not necessarily appear in every 811 PRA document.] Act means the ____________________________________________________________________________________________________________________________(insert current Appropriations) Administrative Costs are allowable at a rate of no more than eight (8) percent of the rental assistance Grant amount awarded, unless approved by HUD. These funds may be used for planning and other costs associated with developing and operating the Section 811 PRA program, including infrastructure and technology needed to operate the program and costs incurred after applicant’s receipt of an Award Letter from HUD and before the execution of the Cooperative Agreement. The costs can include both direct and indirect costs. If a Grantee includes administrative costs in their budget as a direct cost, they cannot charge these costs as part of their indirect cost rate as well, and should instruct th...
Sample 1
Disbarment. Contractor represents and warrants it is not debarred from consideration for contract awards by the Director of the Department of Administrative Services, pursuant to either R.C. 153.02 or R.C. 125.25.
Sample 1
Disbarment. If the final order against the respondent is for disbar- ment, the respondent will not there- after be permitted to practice before the Bureau unless authorized to do so by the Director of Practice pursuant to § 8.72.
Sample 1
Disbarment. To the best of ANDAPHARM's knowledge, it has not and will not use the services of any persons debarred under 21 U.S.C. Section 335(a) or (b) in any capacity associated with or related to the manufacture of the Product. ANDAPHARM also warrants that neither ANDAPHARM nor any of its officers or employees has been convicted of a felony under the U.S. federal law for conduct relating to the * PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. development or approval, including the process for development or approval, of any drug product, new drug application or abbreviated new drug application and neither ANDAPHARM nor any of its officers or employees has been convicted of a felony under the U.S. federal law for conduct relating to the regulation of any product under the Federal Food, Drug and Cosmetic Act. If required, ANDAPHARM shall provide for FDA submission a standard "Debarrment Certification" upon request of BRECKENRIDGE.
Sample 1
AutoNDA by SimpleDocs
Disbarment. Xxxxxx represents and certifies that neither it nor any person or entity employed or engaged by Seller, including without limitation its officers, directors, employees, or agents who provide services in connection with this Agreement (collectively “Personnel”) are currently:
Sample 1

Related to Disbarment

  • Debarment The Contractor certifies that neither it nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from participation in this transaction (contract) by any governmental department or agency. This certification represents a recurring certification made at the time any Order is placed under this Master Agreement. If the Contractor cannot certify this statement, attach a written explanation for review by the Lead State.

  • No Debarment In the course of the Development of the Product, each Party shall not use any employee or consultant who has been debarred by any Regulatory Authority, or, to such Party’s knowledge, is the subject of debarment proceedings by a Regulatory Authority. Each Party shall notify the other Party promptly upon becoming aware that any of its employees or consultants has been debarred or is the subject of debarment proceedings by any Regulatory Authority.

  • Environmental Protection Except as set forth in Schedule 5.13 annexed hereto:

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!